COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey

Institut National de la Santé Et de la Recherche Médicale, France

Status: Completed

Conditions: SARS-COV2 Infection

Treatments: Diagnostic Test: blood test for SARS-COV2 serology

Study type: Observational

Funder types: Other

Identifiers

NCT04470648

C20-50

Details and patient eligibility

About

Study of COVID-19 seroprevalence in precarious population living in shelters of Samusocial de Paris and in staff working in these centers during COVID-19 epidemic.

Full description

After emergence of a new coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV2) responsible for a cluster of respiratory infection at Wuhan, China, on January, 7th 2020, first cases were diagnosed in France in January 24th 2020.

Health care components of Samusocial de Paris (Lits Haltes Soins Santé (LHSS)) were created in 2006. They provide medical care for homeless people and people in social distress not needing an hospitalization. Sometimes there are 3 persons in a bedroom.

In december 2018, a special shelter for isolated women or women in precarious situations opened.

Because of the living conditions in these centers and the difficulty for these populations to respect social distancing and hygiene recommendations.

A first case of COVID-19 was identified on March 8th 2020 in one of these healthcare centers. Other cases were detected in the same center, then in another center on March 16th, then in the dormitory of the women shelter on March 30th.

A recent study showed an important prevalence of SARS-COV2 in residents of a homeless shelter in Boston (36%), most of them were asymptomatic.

Seroprevalence studies are done in general population or in health care workers, but don't include vulnerable people.

It seemed important to us to describe the epidemic in these centers and to study COVID-19 seroprevalence in these particular populations.

Enrollment: 179 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• to have been hosted or working in one the three centers (LHSS Ridder-Plaisance or Saint Michel or Halte femmes) between march and may 2020
• to be aged 18 y or more
• to be able to give an informed consent

Exclusion criteria

• people who refuse to participate
• not being able to give an informed consent
• Person subject to a legal protection measure (safeguard of justice, curatorship or guardianship)
• Person who does not understand the information provided on how to carry out the research
• Obstacle to venous sampling

Trial design

179 participants in 1 patient group

hosted in the center and HCWs at the epidemic period

Description:

people hosted in the health care or in the women center and health care workers working in one these centers during the epidemic time. People with initial positive SARS-COV2 serology will have a second blood test to mesure atibodies kinetic

Treatment:

Diagnostic Test: blood test for SARS-COV2 serology